Skip to main content

Seres Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

MCRB$1.70-14.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Incorporated by Reference · Filed/
ExhibitNumberExhibit DescriptionFormFile No.ExhibitFilingDateFurnishedHerewith
3.1Restated Certificate of Incorporation, filed on July 1, 20158-K001-374653.17/1/15
3.2Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated June 27, 20238-K001-374653.16/28/23
3.3Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 20248-K001-374653.14/8/24
3.4Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 21, 20258-K001-374653.14/22/25
3.6Amended and Restated Bylaws8-K001-374653.11/2/24
10.1Seres Therapeutics, Inc. 2025 Incentive Award Plan8-K001-3746510.14/14/25
10.2Non-Employee Director Compensation Policy*
31.1Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer*
31.2Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*
32.1Section 1350 Certification of Chief Executive Officer**
32.2Section 1350 Certification of Chief Financial Officer**
101.INSInline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document*
101.SCHInline XBRL Taxonomy Extension Schema Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
  • Filed herewith.

** Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.